{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:56:54Z","timestamp":1774558614155,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ygyno.2016.11.006","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T12:18:11Z","timestamp":1479471491000},"page":"65-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial"],"prefix":"10.1016","volume":"144","author":[{"given":"Roberto","family":"Sorio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9lia","family":"Roemer-Becuwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Hilpert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"Kaern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Huizing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petronella","family":"Witteveen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Coeffic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Joachim","family":"L\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles-Briac","family":"Levach\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee Khoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.11.006_bb0005","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ygyno.2015.06.017","article-title":"Why have ovarian cancer mortality rates declined? Part I. Incidence","volume":"138","author":"Sopik","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0010","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.2014.55.3073","article-title":"Breast and ovarian cancer in the older woman","volume":"32","author":"Tew","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0015","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.ejca.2010.02.022","article-title":"EORTC elderly task force position paper: approach to the older cancer patient","volume":"46","author":"Pallis","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.11.006_bb0020","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1093\/annonc\/mdt360","article-title":"Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial","volume":"24","author":"Falandry","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000336829","article-title":"Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience","volume":"35","author":"Hilpert","year":"2012","journal-title":"Onkologie"},{"key":"10.1016\/j.ygyno.2016.11.006_bb0030","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/annonc\/mdi367","article-title":"Non-enrolment of ovarian cancer patients in clinical trials: reasons and background","volume":"16","author":"Harter","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1179\/joc.2007.19.5.577","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience","volume":"19","author":"Germano","year":"2007","journal-title":"J. Chemother."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0040","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00432-012-1221-3","article-title":"A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis","volume":"138","author":"Mahner","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0045","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/annonc\/mdr001","article-title":"Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study","volume":"22","author":"Kurtz","year":"2011","journal-title":"Ann. Oncol."},{"issue":"15s Suppl","key":"10.1016\/j.ygyno.2016.11.006_bb0050","article-title":"Treatment outcomes for older women with advanced ovarian cancer: results from a phase III clinical trial (GOG182)","volume":"28","author":"Tew","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0055","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2007.04.012","article-title":"Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy","volume":"106","author":"Eisenhauer","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.suronc.2004.08.010","article-title":"Poorer survival of elderly patients with ovarian cancer: a population-based study","volume":"13","author":"Petignat","year":"2004","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1757-2215-6-42","article-title":"Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium","volume":"6","author":"Trillsch","year":"2013","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00002512-200017010-00002","article-title":"Drug therapy for gynaecological cancer in older women","volume":"17","author":"van Rijswijk","year":"2000","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ygyno.2016.11.006_bb0075","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/annonc\/mdl400","article-title":"Carboplatin\/cyclophosphamide or carboplatin\/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d\u2019Investigateurs Nationaux pour l'Etude des Cancers Ovariens","volume":"18","author":"Tr\u00e9dan","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0080","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/IGC.0000000000000418","article-title":"Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study","volume":"25","author":"Sabatier","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.11.006_bb0085","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s12885-015-1947-9","article-title":"Under-treatment of elderly patients with ovarian cancer: a population based study","volume":"15","author":"Fourcadier","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2016.11.006_bb0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1040-8428(03)00100-8","article-title":"Ovarian cancer in the elderly","volume":"49","author":"Pignata","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0095","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ygyno.2015.07.007","volume":"138","author":"Woopen","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0100","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0105","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.critrevonc.2012.11.006","article-title":"Bevacizumab in older patients with advanced colorectal or breast cancer","volume":"87","author":"Aprile","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/annonc\/mdr043","article-title":"First-line bevacizumab-containing therapy for breast cancer: results in patients aged \u226570years treated in the ATHENA study","volume":"23","author":"Biganzoli","year":"2012","journal-title":"Ann. Oncol."},{"issue":"Suppl. 6","key":"10.1016\/j.ygyno.2016.11.006_bb0120","volume":"27","author":"Mustea","year":"2016","journal-title":"Ann. Oncol."},{"issue":"Suppl.","key":"10.1016\/j.ygyno.2016.11.006_bb3252","article-title":"Safety and efficacy of extended bevacizumab (BEV) therapy in elderly (\u226570years) patients (pts) treated for newly diagnosed ovarian cancer (OC) in the international ROSiA study","volume":"34","author":"Selle","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2016.11.006_bb0125","doi-asserted-by":"crossref","first-page":"S545","DOI":"10.1016\/S0959-8049(16)31513-1","article-title":"A real life experience of bevacizumab in elderly women with advanced ovarian cancer","volume":"51","author":"Beinse","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.11.006_bb0130","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00432-009-0712-3","article-title":"Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies","volume":"136","author":"Cassidy","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0135","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000320222","article-title":"Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study","volume":"78","author":"Kozloff","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2016.11.006_bb0145","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/annonc\/mdr488","article-title":"Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C","volume":"23","author":"Price","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0150","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/cncr.10385","article-title":"Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma","volume":"94","author":"Gronlund","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.11.006_bb0155","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ygyno.2014.10.028","article-title":"Treatment of ovarian cancer in the older woman","volume":"136","author":"Tew","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.006_bb0160","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/annonc\/mdi368","article-title":"Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study","volume":"16","author":"Freyer","year":"2005","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816315621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816315621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T09:37:55Z","timestamp":1620812275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816315621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0090825816315621"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.11.006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727010269.793552769","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}